French National Agency for Research on Aids and Viral Hepatitis

AIDS Vaccine 2009 - Abstracts

Submission Guidelines

The AIDS Vaccine 2009 Conference invites you to submit an abstract from 17 March 2009 to 15 May 2009.

Individuals submitting abstracts agree that if their abstract is accepted, they will attend the meeting and present their abstract as scheduled. The presenting author should be able to answer substantive questions about all aspects of their study.

Once an abstract has been accepted and scheduled, it cannot be withdrawn. Authors agree to have the abstract published in the Conference Abstract Book and as a supplement to a scientific journal related to the field.


  • Acute HIV/SIV infection
  • Adjuvants
  • Animal Models
  • B Cell Immunity & Neutralizing Antibodies
  • B Cell vaccine concepts & design
  • Clinical Trial Site Development
  • HIV transmission
  • Host Genetic Factors
  • Immune Escape
  • Innate Immunity
  • Mucosal Immunity
  • Novel Immunogens/Inserts
  • Prevention Strategies
  • Prophylactic Vaccine Trials
  • Social/Ethical/Access/Regulatory issues
  • T cell immunity
  • T cell vaccine concepts & design
  • Therapeutic vaccine
  • Vaccine concepts & design
  • Viral diversity

On-Line Abstract Submission

Abstracts must be submitted via the online submission system on this web site. Submitters will be prompted through the electronic submission process.

Click here to view a checklist of the information needed for abstract submission. Please carefully review the abstract prior to its submission. Note that if an abstract has been entered but the “Save and Complete” button has not been clicked, it is not considered submitted and will not be reviewed. Edits to the abstract (other than designating a different category) may be made online after submission up until the deadline of 17:00 GMT - 7, May 15, 2009. Editing a submitted abstract requires use of the abstract ID number that you will receive by email after you have completed the submission process (see Notification and Correspondence below). You may only have one incomplete abstract at a time. You cannot start a second abstract without completing and submitting the first.

Submit an Abstract

Published Abstracts

Accepted abstracts will be published in the AIDS Vaccine 2009 Abstract Book and distributed to registrants. Abstracts will also be published as a supplement to a scientific journal related to the field.

Copyright and Webcast Policy

By submitting an abstract, authors and co-authors transfer any copyrights and grant permission to AIDS Vaccine 2009 to audio/video record oral presentations.

Abstract Selection Process

Abstract submissions will be peer reviewed by the Conference Organizers and members of the Scientific Organizing Committee. To minimize subjectivity in the scoring process, any reviewer with a conflict of interest (as defined by NIH rules, e.g., co-authorship, financial interest, or scientific/personal conflict with the authors that could affect objectivity of scoring) will be excluded from scoring or discussing the abstract in question. In the final rankings, mean score and standard deviation will be calculated, and the reviewers' scores will be anonymous. Abstract acceptance is based upon abstract quality, the potential significance of the observations, and the rigor with which the scientific methods were applied. Further, the Conference Organizers consider thematic balance in determining which abstracts will be presented orally.

Late Breaker Abstract Information

Late Breaker Abstract Submissions will be accepted from July 6, 2009 - August 20, 2009.

Poster Specifications

To Be Determined

© 2005 - 2009 Global HIV Vaccine Enterprise